2026-07-02 Download PDF RNS Number : 7005K PureTech Health PLC 02 July 2026 2 July 2026 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION PureTech Health plc PureTech Announces Completion of**$180 Million****Financing for Founded Entity Celea…
2026-07-02
Download PDF

RNS Number : 7005K
PureTech Health PLC
02 July 2026
2 July 2026
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION
PureTech Health plc
PureTech Announces Completion of**$180 Million****Financing for Founded Entity Celea Therapeutics** to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
PureTech launches Celea as an independent company backed by a syndicate of top-tier healthcare investors, enabling PureTech's transition to a lean operating model
PureTech retains 35.4% ownership of Celea in addition to non-dilutive royalties, milestone payments, and sublicense income, maintaining long-term potential upside
Proceeds enable Celea to initiate SURPASS-IPF, the first head-to-head Phase 3 trial in IPF, evaluating superiority of deupirfenidone as a potential new standard of care
PureTech Health plc (LSE: PRTC) ("PureTech", "Company") today announces that its Founded Entity, Celea Therapeutics Inc. ("Celea"), has completed a $180 million financing and associated asset transfer from PureTech (the "Transaction") with participation from a syndicate comprising top-tier healthcare investors, including RA Capital Management, Leaps by Bayer, and founder PureTech, alongside a large, U.S.-based healthcare-focused fund and a leading sovereign wealth fund (the "Celea Investors"). The Transaction establishes Celea as an independently funded company, with proceeds supporting the planned early Q3 2026 initiation of the Phase 3 SURPASS-IPF trial of deupirfenidone (LYT-100).
Deupirfenidone is an investigational next-generation antifibrotic with the potential to serve as a new standard of care for people living with idiopathic pulmonary fibrosis (IPF). The programme was advanced by PureTech through successful Phase 2b development and Phase 3 readiness and is now positioned to begin pivotal development with dedicated external capital under Celea. The Transaction is consistent with the strategic priorities outlined by PureTech in 2025, enabling PureTech to retain meaningful ownership and significant non-dilutive economics under a lean operating model.
Robert Lyne**, Chief Executive Officer ofPureTechcommented:**
"The completion of Celea's $180 million financing marks a transformative milestone for both PureTech and Celea. The participation from a distinguished syndicate of leading healthcare investors provides powerful third-party validation of the deupirfenidone programme and the significant progress achieved to date, underscoring the meaningful commercial opportunity we collectively believe it represents.
With this financing, Celea is now positioned to initiate the first-ever industry-sponsored head-to-head Phase 3 trial in IPF. Success in this pivotal trial has the potential to redefine the treatment landscape, delivering significant benefit for patients and value for shareholders.
This Transaction establishes Celea as an independent company with dedicated capital to advance deupirfenidone and a high-quality syndicate to support the company's continued growth. To that end, PureTech is reserving $70 million beyond our $30 million participation in this round to support Celea based on our conviction in the deupirfenidone programme, especially in light of recent public valuations of late-stage clinical assets in the pulmonary space.
For PureTech, the Transaction delivers on the strategy we outlined in 2025. By establishing a path for the continued development of deupirfenidone with third-party capital, the Transaction enables PureTech's transition to a lean operating model while maintaining meaningful ownership in Celea and significant long-term economic upside.
More broadly, this milestone reinforces PureTech's track record of advancing differentiated programmes to key value-inflection points and positioning them to attract high-quality, substantial third-party investment. This disciplined approach remains central to our strategy of continuing to create a diversified portfolio with multiple future value drivers, generating innovative medicines for patients and value for shareholders."
Background to and summary of the investment in Celea
Consistent with the strategic priorities outlined by PureTech in 2025, Celea was founded to advance the development of deupirfenidone as an independently financed Founded Entity. The Transaction provides a dedicated team and external capital to support the programme's continued development, while enabling PureTech to retain 35.4% of the fully diluted share capital in Celea and long-term economic participation through tiered royalties, milestone payments, and sublicense income (as described below) as PureTech continues its transition to a lean operating model.
On 29 June 2026, the Celea Investors made an initial investment of an aggregate amount of approximately $75 million in Celea for Series Seed Preferred stock ("Series Seed Preferred") priced at $1.93 per share (the "Series Seed Preferred Original Issue Purchase Price"). This initial investment was the first step of the larger, completed Series Seed strategic investment in Celea of an aggregate amount equal to $180 million, of which PureTech contributed $30 million, and the remaining investors contributed $150 million in aggregate in exchange for Celea's Series Seed Preferred.
PureTech has also reserved $70 million from existing cash resources to potentially support Celea in the future. As previously guided in PureTech's 2025 Annual Report and Accounts, PureTech has operational runway at least through the end of 2028, which accounts for the full deployment of the additional $70 million reserved for Celea.
In connection with the Transaction, PureTech has transferred certain assets to Celea (the "Transferred Assets"), which include certain intellectual property, contracts pertaining to services solely dedicated to the Transferred Assets, product inventory, regulatory documentation, data and other assets related to the deupirfenidone technology developed by PureTech and its affiliates pursuant to an Asset Transfer Agreement (the "Transfer Agreement") (the "Transfer").
As partial consideration for the Transferred Assets, Celea has issued 40 million shares of Junior Preferred stock (the "Junior Preferred Stock") to PureTech, with a per share liquidation preference of $1.93 per share (the "Junior Preferred Original Purchase Price"). The Junior Preferred Stock will be junior to the Series Seed Preferred with respect to liquidation preference (but not in relation to non-economic rights). In addition to the Junior Preferred Stock, PureTech is also entitled to receive tiered royalties, milestone payments, and sublicense income, as described below. PureTech's current intention is to retain its equity holding in Celea to ensure alignment with the other Celea Investors.
Celea and the Transferred Assets were ascribed a value of $100 million prior to the Transaction, with a fully-diluted post-money valuation of $302.5 million.
In light of the size of the Transferred Assets relative to PureTech, the Transfer by PureTech to Celea constitutes a 'significant transaction' for the purposes of the UK Listing Rules made by the UK Financial Conduct Authority ("FCA") and is, therefore, notifiable in accordance with UKLR 7.3.1R and 7.3.2R. In accordance with the UK Listing Rules, the Transfer is not subject to shareholder approval. Additional information pertaining to UKLR 7.3.1R and 7.3.2R and their respective annexes may be found in the appendix further below.
Rationale for the Transaction and the Transfer
The PureTech Board of Directors (the "Board") unanimously believes the Transaction and the associated Transfer is in the best interests of the Company's shareholders as a whole for the following reasons:
· The Transaction is consistent with PureTech's strategy of attracting third-party capital for its Founded Entities through dedicated vehicles such as Celea, while retaining significant long-term economic participation in future value creation.
· The Transaction is consistent with PureTech's broader strategy of creating a more diversified value proposition for PureTech's shareholders by providing access to multiple programmes, companies, and future value-creating milestones across the portfolio, thereby reducing reliance on any single programme or financing event.
· PureTech's investment of $30 million as part of the Transaction, and the $70 million of capital reserved to potentially support Celea in the future, demonstrates PureTech's continued conviction in the deupirfenidone programme and aligns its interests with those of a syndicate of leading healthcare investors now supporting Celea.
· The Transaction brings together a syndicate of leading healthcare investors, providing external validation of the deupirfenidone programme and access to substantial expertise in the development and commercialisation of biopharmaceutical products.
· The Transaction provides a capital structure that supports continued development of deupirfenidone while preserving flexibility for future financing decisions to be made by Celea and its board based on the needs of the business and market conditions at the time.
· PureTech will have continued involvement in Celea through its rights to designate members of Celea's Board of Directors.
Expected effects of the Transaction and Transfer on the Company
The Transaction serves to launch Celea as an independent operating company. As a result, the assets, liabilities, and spend associated with the deupirfenidone programme will no longer be reflected in PureTech's financial statements and results. This will serve to significantly reduce PureTech's overall operating expense and allow for a leaner operating model.
The Transferred Assets did not generate any profit for PureTech during the year-ended 31 December 2025, although the Company had external R&D expenses related to the deupirfenidone programme of approximately $31.0 million, which accounted for approximately 70% of the Company's total external R&D spend. Following the completion of the Transaction, PureTech holds 35.4% of the fully diluted share capital in Celea.
The information required by UKLR 7 Annex 2.2(2) and 2.2(3) is not available and cannot be produced in accordance with the requirements of UKLR Annex 2.2(1)(a). As above, the Board ascribed a value of $100 million to Celea and the Transferred Assets prior to the Transaction based on the terms agreed among the Celea Investors to enter into the Transaction. In light of this, the Board considered that the consideration for the Transferred Assets, in the form of the Junior Preferred Stock and the ongoing PureTech Non-Dilutive Economics (as defined below), to be reflective of the value ascribed to Celea and the Transferred Assets.
As such, the Board deemed the consideration for the Transferred Assets fair as far as the shareholders of the Company are concerned.
PureTech Non-Dilutive Economics
As partial consideration for the Transferred Assets and as part of the Transfer Agreement, PureTech and Celea entered into an agreement under which Celea will pay PureTech tiered royalties on annual net sales of Celea's products that use the deupirfenidone technology until the later of the last-to-expire patent or ten (10) years from the first commercial sale of such Celea product. Under the PureTech royalty, PureTech will receive:
· 1% of annual net sales less than $1 billion
· 2% of annual net sales equal to or greater than $1 billion but less than $2 billion
· 3% of annual net sales equal to or greater than $2 billion
These royalty amounts are potentially subject to customary reductions based on future events.
PureTech is also entitled to receive up to $190 million in aggregate milestone payments in connection with various sales milestones, including:
· $15 million upon the first commercial sale of a Celea product in the United States;
· $25 million upon the first achievement of $500 million in worldwide net sales of all Celea products in a single calendar year;
· $50 million upon the first achievement of $1 billion in worldwide net sales of all Celea products in a single calendar year; and
· $100 million upon the first achievement of $3 billion in worldwide net sales of all Celea products in a single calendar year.
PureTech is also entitled to receive 20% of sublicense income generated by Celea with respect to the Transferred Assets (together with the tiered royalties and milestone payments, the "PureTech Non-Dilutive Economics").
Series Seed Preferred rights
In the event of any liquidation, dissolution or winding up of Celea, the proceeds shall be paid first to the holders of Series Seed Preferred in an amount per share equal to one times the respective Series Seed Preferred Original Purchase Price, plus declared and unpaid dividends, and next to the holders of Junior Preferred Stock in an amount per share equal to one times the Junior Preferred Original Purchase Price, plus declared and unpaid dividends.
Save in relation to voting matters related to the Junior Preferred Stock, PureTech's voting power in Celea will be limited to 49% at all times, whether when voting with the common stock of Celea on an as-converted basis or when voting as part of the preferred stock, with any preferred stock held by PureTech in excess of this threshold automatically converting into a new class of non-voting preferred stock.
As long as 50% of the preferred stock remains outstanding, Celea will maintain a list of reserved matters that requires the written consent of the holders of a majority of the outstanding preferred stock, which must include the lead investor.
The Series Seed Preferred carries an annual 8%, non-cumulative dividend, payable in cash or payment-in-kind, when and if declared by Celea's board of directors, prior and in preference to any declaration or payment of other dividends.
Governance
The Celea board of directors currently has six directors and may have up to nine directors in total. In addition to Celea's Chief Executive Officer, who will also serve on the board, and two independent directors who will be added at a later date, PureTech has the right to designate three directors, one of whom - if proposed - would require the lead investor's approval; the lead investor has the right to designate two directors; and RA Capital Management has the right to designate one director.